AU2007227398C1 - Compounds for the treatment of spinal muscular atrophy and other uses - Google Patents

Compounds for the treatment of spinal muscular atrophy and other uses Download PDF

Info

Publication number
AU2007227398C1
AU2007227398C1 AU2007227398A AU2007227398A AU2007227398C1 AU 2007227398 C1 AU2007227398 C1 AU 2007227398C1 AU 2007227398 A AU2007227398 A AU 2007227398A AU 2007227398 A AU2007227398 A AU 2007227398A AU 2007227398 C1 AU2007227398 C1 AU 2007227398C1
Authority
AU
Australia
Prior art keywords
amended
alkyl
group
haloalkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007227398A
Other languages
English (en)
Other versions
AU2007227398A1 (en
AU2007227398B2 (en
AU2007227398A8 (en
Inventor
Keith D. Barnes
David Fairfax
Jill Heemskerk
Graham Johnson
Matthew Robert Johnson
John M. Mccall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curia Global Inc
US Department of Health and Human Services
Original Assignee
Albany Molecular Research Inc
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Molecular Research Inc, Government of the United States of America filed Critical Albany Molecular Research Inc
Publication of AU2007227398A1 publication Critical patent/AU2007227398A1/en
Publication of AU2007227398A8 publication Critical patent/AU2007227398A8/en
Assigned to GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, ALBANY MOLECULAR RESEARCH, INC. reassignment GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Request for Assignment Assignors: ALBANY MOLECULAR RESEARCH, INC., GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SCIENCE APPLICATIONS INTERNATIONAL CORPORATION (SAIC)
Assigned to ALBANY MOLECULAR RESEARCH, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES reassignment ALBANY MOLECULAR RESEARCH, INC. Amend patent request/document other than specification (104) Assignors: ALBANY MOLECULAR RESEARCH, INC., GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Application granted granted Critical
Publication of AU2007227398B2 publication Critical patent/AU2007227398B2/en
Publication of AU2007227398C1 publication Critical patent/AU2007227398C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007227398A 2006-03-17 2007-03-16 Compounds for the treatment of spinal muscular atrophy and other uses Ceased AU2007227398C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78329206P 2006-03-17 2006-03-17
US60/783,292 2006-03-17
PCT/US2007/006772 WO2007109211A2 (en) 2006-03-17 2007-03-16 1-oxo-isoindoline compounds for the treatment of spinal muscular atrophy and other uses

Publications (4)

Publication Number Publication Date
AU2007227398A1 AU2007227398A1 (en) 2007-09-27
AU2007227398A8 AU2007227398A8 (en) 2008-11-27
AU2007227398B2 AU2007227398B2 (en) 2012-09-27
AU2007227398C1 true AU2007227398C1 (en) 2013-05-30

Family

ID=38477008

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007227398A Ceased AU2007227398C1 (en) 2006-03-17 2007-03-16 Compounds for the treatment of spinal muscular atrophy and other uses

Country Status (10)

Country Link
US (2) US8110681B2 (https=)
EP (1) EP2027088A2 (https=)
JP (2) JP2009530306A (https=)
CN (1) CN101500995A (https=)
AU (1) AU2007227398C1 (https=)
BR (1) BRPI0708801A2 (https=)
CA (1) CA2645426A1 (https=)
IL (1) IL194153A0 (https=)
WO (1) WO2007109211A2 (https=)
ZA (1) ZA200807936B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267712A1 (en) 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
JP5543354B2 (ja) * 2007-10-19 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ γ−セクレターゼのアミン結合調節物質
JP5632612B2 (ja) * 2007-12-05 2014-11-26 あすか製薬株式会社 ラクタム化合物又はその塩及びｐｐａｒ活性化剤
US8722723B2 (en) 2008-02-28 2014-05-13 Research Foundation Itsuu Laboratory Aromatic amide derivative
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
AU2010341573B2 (en) 2009-12-22 2016-10-13 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
US9073895B2 (en) * 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
NO3175985T3 (https=) 2011-07-01 2018-04-28
EP2772480B2 (en) * 2011-10-25 2020-12-09 Shionogi & Co., Ltd. Hiv replication inhibitor
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP2812004B1 (en) * 2012-02-10 2018-06-27 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US9212209B2 (en) * 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
WO2014077401A1 (ja) * 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
CA2894992A1 (en) * 2012-12-24 2014-07-03 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
EP3186241B1 (en) 2014-08-29 2020-10-07 CHDI Foundation, Inc. Probes for imaging huntington protein
CN105801556A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
CN107709311B (zh) * 2015-07-14 2020-09-25 豪夫迈·罗氏有限公司 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作为eaat3抑制剂的用途
WO2017066103A1 (en) * 2015-10-16 2017-04-20 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
EA201800367A1 (ru) * 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
EP3509588B1 (en) * 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
JP2020523365A (ja) 2017-06-14 2020-08-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを改変する方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
HRP20240935T1 (hr) 2018-06-27 2024-11-22 Ptc Therapeutics, Inc. Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
JP7649257B2 (ja) 2019-05-13 2025-03-19 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
WO2021014428A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems
KR102186761B1 (ko) 2020-06-03 2020-12-04 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
EP4251149A4 (en) * 2020-11-24 2024-10-30 Merck Sharp & Dohme LLC MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
CN115141097A (zh) * 2022-06-27 2022-10-04 重庆医药高等专科学校 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的生产线系统
CN115304472A (zh) * 2022-06-27 2022-11-08 重庆医药高等专科学校 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的合成方法
KR102883783B1 (ko) * 2022-12-15 2025-11-12 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물 제조방법
KR102597093B1 (ko) * 2023-06-07 2023-11-03 옙바이오 주식회사 줄기세포 노화 억제 신규 화합물 및 이의 약학적 용도
CN117740969B (zh) * 2023-11-30 2025-01-10 杭州志呈科技有限公司 一种吲哚布芬杂质检测方法及其应用
CN120965663A (zh) * 2024-05-17 2025-11-18 北京理工大学 sEH抑制剂化合物、药物组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) * 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126691A (en) 1968-03-27 1978-11-21 Ciba-Geigy Corporation Tertiary aminoacids
DE2034240C2 (de) 1968-03-27 1982-12-02 CIBA-GEIGY AG, 4002 Basel Isoindolinderivate, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung
US3641040A (en) * 1968-03-27 1972-02-08 Ciba Geigy Corp Tertiary amino phenyl acetic acids
US3542806A (en) 1968-03-29 1970-11-24 Robins Co Inc A H 2-(1-substituted-3-pyrrolidinyl)-isoindolines
DE2046992A1 (en) * 1970-09-24 1972-03-30 Merck Patent Gmbh, 6100 Darmstadt Isoindolinophenyl-alkanoic acid esters and salts - - antiphlogistic, antipyretic and analgesic agents
DE2154525A1 (de) * 1970-11-05 1972-06-15 Carlo Erba S.P.A., Mailand (Italien) Isoindolinderivate und Verfahren zu ihrer Herstellung
FI53702C (fi) * 1971-11-22 1978-07-10 Erba Carlo Spa Foerfarande foer framstaellning av isoindolinderivat
US3890346A (en) * 1972-03-22 1975-06-17 Monsanto Co Process for the preparation of N-arylphthalimidines
GB1413173A (en) * 1972-07-07 1975-11-12 Bp Chem Int Ltd Polymerisation process
US3997669A (en) 1972-12-26 1976-12-14 Ciba-Geigy Corporation Tertiary aminoacids
JPS5233667A (en) * 1975-09-11 1977-03-14 Fuji Kagaku Kogyo Kk Process for preparation of hydrogenated 1-oxo-isoindoline derivatives
IT1113035B (it) * 1979-03-06 1986-01-20 Erba Farmitalia Esteri c alla 3 - c alla 4 aclhilici di 1-oxo-2- aperta par.graffa p aperta par. quadrata (alfa-metil) -carbossimetil chiusa par. quadrata - fenil chiusa par. graffa- isoindolina
JPS5644686A (en) 1979-09-21 1981-04-23 Hodogaya Chem Co Ltd Pressure-sensitive reproducing paper
JPS5645955A (en) 1979-09-21 1981-04-25 Hodogaya Chem Co Ltd 6-(2,3-dihydroisoindol-2-yl)fluoran compound
JPS5750960A (en) * 1980-09-10 1982-03-25 Hisamitsu Pharmaceut Co Inc Preparation of novel 4- 1-oxo-2-isoindolinyl acetophenone
JPS5845088A (ja) 1981-09-09 1983-03-16 Sumitomo Chem Co Ltd 記録紙
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
JPH03181478A (ja) 1989-12-08 1991-08-07 Banyu Pharmaceut Co Ltd ピリドンカルボン酸誘導体
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5567718A (en) 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
EP1642575B1 (en) * 1997-03-10 2009-10-28 Loma Linda University Medical Center Use of r-carprofen for the prevention of alzheimer's disease
CO5160341A1 (es) 1998-12-23 2002-05-30 Schering Corp Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
WO2002046164A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
AU2003256755A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2004036181A2 (en) 2002-10-17 2004-04-29 The Trustees Of The University Of Pennsylvania Method of treating neurological diseases and disorders
EP1566378B1 (en) 2002-11-26 2012-08-15 Maruishi Pharmaceutical Co., Ltd. Isoindoline derivative
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2006050451A2 (en) 2004-11-02 2006-05-11 Whitehead Institute For Biomedical Research Methods and compositions to treat motor neuron disease
US8207213B2 (en) 2006-02-03 2012-06-26 Glaxo Group Limited Benzoisoindole derivatives for the treatment of pain
US8044209B2 (en) 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) * 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lunn, M.R. et al. Chemistry and Biology 2004, 11(11), 1489-1493 *

Also Published As

Publication number Publication date
CN101500995A (zh) 2009-08-05
JP2009530306A (ja) 2009-08-27
WO2007109211A2 (en) 2007-09-27
US20090312323A1 (en) 2009-12-17
ZA200807936B (en) 2009-12-30
WO2007109211A8 (en) 2009-02-12
JP2013116901A (ja) 2013-06-13
IL194153A0 (en) 2009-08-03
AU2007227398A1 (en) 2007-09-27
BRPI0708801A2 (pt) 2011-06-14
US8110681B2 (en) 2012-02-07
EP2027088A2 (en) 2009-02-25
AU2007227398B2 (en) 2012-09-27
AU2007227398A8 (en) 2008-11-27
WO2007109211A3 (en) 2007-12-13
CA2645426A1 (en) 2007-09-27
US20120083495A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
AU2007227398C1 (en) Compounds for the treatment of spinal muscular atrophy and other uses
EP2215074B1 (en) Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
JP4964380B2 (ja) ピラゾールカルボン酸の三環式誘導体、その製造法およびそれを含む医薬組成物
JP2005255685A (ja) カンナビノイド受容体に作用する新規なピラゾール類似体
JP5009151B2 (ja) Ｂｃｒｐ／ａｂｃｇ２阻害剤
CN101663033A (zh) 作为smo拮抗剂的三唑衍生物
JPH10511384A (ja) 多薬剤耐性のモジュレーターとしてのピペラジン２，５ジオン誘導体
CN115703761A (zh) 作为wwp1抑制剂的化合物及其应用
FR2920023A1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
JPWO2005080322A1 (ja) フルオレン誘導体
CN106459072A (zh) Wnt信号传导途径的抑制剂
EP3810133A1 (en) Method of treating a condition associated with neurodegeneration using inhibitors of oat3
US20080161419A1 (en) Prophylactic Antimigraine Agents
CN107250120A (zh) 作为Wnt信号通路抑制剂的1,3,4‑噻二唑‑2‑基‑苯甲酰胺衍生物
CN108064222A (zh) N-苯基-(吗啉-4-基或哌嗪基)乙酰胺衍生物及其作为wnt信号通路抑制剂的用途
WO2012142459A1 (en) Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
CN104774188A (zh) 苯并杂环类或苯并杂芳环类衍生物、其制备方法及其在医药上的应用
CA2389766C (fr) Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN114555603A (zh) 制备作为食欲素受体调节剂的(2h-1,2,3-三唑-2-基)苯基化合物的改进的合成方法
HK1120258B (en) Bcrp/abcg2 inhibitor
JP2018533600A (ja) ７−アザインドリン−２−オン誘導体又はその薬学的に許容される塩を有効成分として含有する医薬組成物
HK1234400A1 (zh) Wnt信号传导途径的抑制剂
TW200530191A (en) Imidazoline derivatives having CB1-antagonistic activity

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ FROM 1-OXO-ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES TO: COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES

TH Corrigenda

Free format text: IN VOL 22, NO 40, PAGE(S) 4743 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ALBANY MOLECULAR RESEARCH, INC.; SCIENCE APPLICATIONS INTERNATIONAL CORPORATION (SAIC) AND GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, APPLICATION NO. 2007227398, UNDER INID (22), CORRECT THE FILING DATE OF THE APPLICATION TO 16 MARCH 2007

PC1 Assignment before grant (sect. 113)

Owner name: GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRES

Free format text: FORMER APPLICANT(S): GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; SCIENCE APPLICATIONS INTERNATIONAL CORPORATION (SAIC); ALBANY MOLECULAR RESEARCH, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 DEC 2012 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 DEC 2012 AND 18 JAN 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired